RU96101193A - Фрагменты антител в терапии - Google Patents
Фрагменты антител в терапииInfo
- Publication number
- RU96101193A RU96101193A RU96101193/14A RU96101193A RU96101193A RU 96101193 A RU96101193 A RU 96101193A RU 96101193/14 A RU96101193/14 A RU 96101193/14A RU 96101193 A RU96101193 A RU 96101193A RU 96101193 A RU96101193 A RU 96101193A
- Authority
- RU
- Russia
- Prior art keywords
- septic shock
- igg
- tnfα
- fab fragment
- symptoms
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010040070 Septic Shock Diseases 0.000 claims 8
- 230000036303 septic shock Effects 0.000 claims 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000006386 neutralization reaction Methods 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (1)
1. Способ нейтрализации TNFα у пациента, нуждающегося в такой нейтрализации, предусматривающий введение указанному пациенту IgG-Fab-фрагмента, обладающего реактивностью по отношению к TNFα, где указанный Fab-фрагмент происходит от поликлонального IgG.
2. Способ по п.1, где указанный пациент страдает септическим шоком или имеет симптомы септического шока.
3. Способ предупреждения или частичного ослабления септического шока или симптомов септического шока у пациента, предусматривающий введение указанному пациенту IgG-Fab-фрагмента, обладающего реактивностью по отношению к TNFα, где указанный фрагмент происходит от поликлонального IgG.
4. Способ по п.2 или 3, где указанные симптомы септического шока вызваны введением моноклонального антитела ОКТЗ или функционально эквивалентного антитела.
5. Способ по п.2 или 3, где указанные симптомы септического шока вызваны реакцией Джарича-Херксхеймера.
6. IgG-Fab-фрагмент, происходящий от поликлонального IgG, являющегося реактивным по отношению к TNFα, и предназначенный для использования его в медицине.
7. Применение IgG-Fab-фрагмента, происходящего от поликлонального IgG, являющегося реактивным по отношению к TNFα, в изготовлении лекарственного средства для лечения пациентов, нуждающихся в нейтрализации TNFα.
8. Применение по п.7, где указанный пациент страдает септическим шоком или имеет симптомы септического шока.
8. Применение по п.7, где указанный пациент страдает септическим шоком или имеет симптомы септического шока.
9. Фармацевтическая композиция, содержащая IgG-Fab-фрагмент, обладающий реактивностью по отношению к TNFα, и физиологически приемлемый носитель, где указанный Fab-фрагмент происходит от поликлонального IgG.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939311507A GB9311507D0 (en) | 1993-06-03 | 1993-06-03 | Antibody fragments |
| GB9311507.9 | 1993-06-03 | ||
| GB9402593A GB9402593D0 (en) | 1994-02-10 | 1994-02-10 | Antibody fragments |
| GB9402593.9 | 1994-02-10 | ||
| PCT/GB1994/001209 WO1994029347A1 (en) | 1993-06-03 | 1994-06-03 | Antibody fragments in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU96101193A true RU96101193A (ru) | 1998-05-10 |
| RU2139092C1 RU2139092C1 (ru) | 1999-10-10 |
Family
ID=26303001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU96101193A RU2139092C1 (ru) | 1993-06-03 | 1994-06-03 | Фрагменты антител в терапии |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5733742A (ru) |
| EP (3) | EP0916678A3 (ru) |
| JP (1) | JP2953782B2 (ru) |
| AT (2) | ATE157100T1 (ru) |
| AU (2) | AU6852594A (ru) |
| CA (1) | CA2163032C (ru) |
| DE (2) | DE69420137T2 (ru) |
| DK (2) | DK0703925T3 (ru) |
| ES (2) | ES2108460T3 (ru) |
| FI (1) | FI955798A7 (ru) |
| GB (1) | GB2294267B (ru) |
| GR (2) | GR3025133T3 (ru) |
| NO (1) | NO954643D0 (ru) |
| NZ (1) | NZ266838A (ru) |
| RU (1) | RU2139092C1 (ru) |
| WO (2) | WO1994029347A1 (ru) |
Families Citing this family (207)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| GB9517538D0 (en) * | 1995-08-26 | 1995-10-25 | Therapeutic Antibodies Inc | Production and therapeutic combinations, of antibodies |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| CA2249206A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| JP2000515735A (ja) | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
| US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| US5990281A (en) | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
| US6136958A (en) | 1996-09-30 | 2000-10-24 | Genentech, Inc. | Antibodies to vertebrate smoothened proteins |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| JP2001523977A (ja) | 1997-06-05 | 2001-11-27 | ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ | Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子 |
| CA2293740A1 (en) | 1997-06-18 | 1998-12-23 | Genentech, Inc. | Apo-2dcr, a tnf-related receptor |
| ES2316182T3 (es) | 1998-01-15 | 2009-04-01 | Genentech, Inc. | Ligando apo-2. |
| IL139419A0 (en) | 1998-06-12 | 2001-11-25 | Genentech Inc | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| WO2002009755A2 (en) | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Apo-2l receptor agonist and cpt-11 synergism |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| CA2425779C (en) | 2000-10-12 | 2013-08-06 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
| US6709655B2 (en) | 2001-02-28 | 2004-03-23 | Instituto Bioclon, S.A. De C.V. | Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| US7811992B2 (en) | 2002-02-06 | 2010-10-12 | Stasys Technologies, Inc. | Anti-infarction molecules |
| WO2003089624A2 (en) | 2002-03-25 | 2003-10-30 | Uab Research Foundation | Fc receptor homolog, reagents, and uses thereof |
| AU2002315115B2 (en) | 2002-06-14 | 2008-10-16 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer | Methods of treating and preventing colitis involving IL-13 and NK-T cells |
| WO2004013160A2 (en) | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| EP1576351A4 (en) | 2002-11-26 | 2010-06-23 | Univ Utah Res Found | MICROPOROUS MATERIALS; METHODS AND ARTICLES FOR LOCALIZING AND QUANTIFYING ANALYTES |
| US7597936B2 (en) | 2002-11-26 | 2009-10-06 | University Of Utah Research Foundation | Method of producing a pigmented composite microporous material |
| MXPA05005921A (es) * | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| US7335759B2 (en) * | 2002-12-02 | 2008-02-26 | Universidad Nacional Autónoma de Méxica (UNAM) | Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides |
| US7141015B2 (en) * | 2003-05-09 | 2006-11-28 | Bernard Joseph Ruane | Expandable and pivotally adjustable surgical retractor |
| US20060210563A1 (en) * | 2003-07-25 | 2006-09-21 | Juan Lopez De Silanes | Administration of anti-cytokine f(ab')2 antibody fragments |
| FR2859725B1 (fr) * | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
| JP2007518422A (ja) | 2004-01-21 | 2007-07-12 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | 変異体ナトリウムチャンネルＮａν１．７およびそれに関連する方法 |
| AU2005229457B2 (en) | 2004-03-30 | 2010-11-25 | Glaxo Group Limited | Immunoglobulins |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| US7381802B2 (en) * | 2005-04-15 | 2008-06-03 | Universidad Nacional Autónoma De México (UNAM) | Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom |
| ZA200710599B (en) | 2005-04-15 | 2009-08-26 | Genentech Inc | HGF Beta chain variants |
| JP5757495B2 (ja) | 2005-05-16 | 2015-07-29 | アッヴィ バイオテクノロジー リミテッド | びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用 |
| AU2005332058B2 (en) | 2005-05-19 | 2011-12-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| US8470965B2 (en) | 2006-03-01 | 2013-06-25 | University Of Utah Research Foundation | Methods and compositions related to cyclic peptide synthesis |
| US9365622B2 (en) | 2006-03-01 | 2016-06-14 | University Of Utah Research Foundation | Methods and compositions related to cyclic peptide synthesis |
| WO2007117490A2 (en) | 2006-04-05 | 2007-10-18 | Abbott Biotechnology Ltd. | Antibody purification |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
| AU2007269714A1 (en) | 2006-07-03 | 2008-01-10 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
| EP2104516B1 (en) | 2006-11-01 | 2015-01-07 | University of Rochester | Methods and compositions related to the structure and function of apobec3g |
| WO2008085794A2 (en) | 2007-01-03 | 2008-07-17 | Burnham Institute For Medical Research | Methods and compositions related to clot binding compounds |
| EP2115173B1 (en) | 2007-01-08 | 2011-09-21 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Slco1b3 genotype |
| US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US9068003B2 (en) | 2007-01-10 | 2015-06-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US8097588B2 (en) | 2007-02-08 | 2012-01-17 | Sanford-Burnham Medical Research Institute | Trophinin-binding peptides and uses thereof |
| WO2009023306A2 (en) | 2007-05-09 | 2009-02-19 | Burnham Institute For Medical Research | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
| EP2164957B1 (en) | 2007-05-23 | 2017-07-12 | The UAB Research Foundation | Detoxified pneumococcal neuraminidase and uses thereof |
| US20100303813A1 (en) | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| EP2268664B1 (en) | 2007-12-03 | 2017-05-24 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Doc1 compositions and methods for treating cancer |
| KR20100120289A (ko) | 2008-01-15 | 2010-11-15 | 애보트 게엠베하 운트 콤파니 카게 | 분말상 단백질 조성물 및 이의 제조 방법 |
| HUE024541T2 (hu) | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
| WO2010019120A1 (en) | 2008-08-15 | 2010-02-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma |
| US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
| PL2172211T3 (pl) | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| US20120070443A1 (en) | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| MY150984A (en) | 2008-12-12 | 2014-03-31 | Boehringer Ingelheim Int | Anti-agf antibodies |
| TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| WO2011020107A2 (en) | 2009-08-14 | 2011-02-17 | Georgetown University | Compositions and methods for detection and treatment of breast cancer |
| EP2485768A1 (en) | 2009-10-07 | 2012-08-15 | Sanford-Burnham Medical Research Institute | Methods and compositions related to clot-binding lipid compounds |
| JP2013510871A (ja) | 2009-11-12 | 2013-03-28 | ジェネンテック， インコーポレイテッド | 樹状突起棘の密度を促す方法 |
| WO2011080050A2 (en) | 2009-12-11 | 2011-07-07 | Novartis Ag | Binding molecules |
| EP2512497A1 (en) | 2009-12-18 | 2012-10-24 | Sanford-Burnham Medical Research Institute | Methods and compositions related to clot-binding compounds |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| UY33202A (es) | 2010-01-28 | 2011-08-31 | Glaxo Group Ltd | Proteínas de unión a cd127 |
| US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US20110293629A1 (en) | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| TW201210612A (en) | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
| US8916152B2 (en) | 2010-06-14 | 2014-12-23 | Lykera Biomed Sa | S100A4 antibodies and therapeutic uses thereof |
| US8512295B2 (en) | 2010-08-19 | 2013-08-20 | West Pharmaceutical Services, Inc. | Rigid needle shield |
| US9051619B2 (en) | 2011-03-25 | 2015-06-09 | Florida Agricultural and Mechanical University (FAMU) | Methods and compositions for prostate cancer metastasis |
| CA2827787A1 (en) | 2011-03-30 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| PL221015B1 (pl) * | 2011-04-11 | 2016-02-29 | Akademia Medyczna Im Piastów Śląskich | Sposób otrzymywania inhibitorów cysteinowych peptydaz o czystości elektroforetycznej z materiałów biologicznych |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US20130004484A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| CA2850178C (en) | 2011-09-30 | 2020-02-25 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| WO2013060872A1 (en) | 2011-10-27 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| US9177997B2 (en) | 2011-12-13 | 2015-11-03 | Sony Corporation | Memory device |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| IN2015MN00001A (ru) | 2012-06-08 | 2015-10-16 | Univ Kinki | |
| EP2870238A4 (en) | 2012-07-05 | 2016-03-09 | Ohio State Innovation Foundation | COMPOSITIONS AND METHODS RELATED TO VIRAL VACCINES |
| EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| US20140094383A1 (en) | 2012-10-02 | 2014-04-03 | Ohio State Innovation Foundation | Tethered Lipoplex nanoparticle Biochips And Methods Of Use |
| MX367136B (es) | 2012-10-18 | 2019-08-06 | Inosan Biopharma S A Star | Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune. |
| US10407503B2 (en) | 2012-11-30 | 2019-09-10 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-Met |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9783576B2 (en) | 2013-06-11 | 2017-10-10 | Sanford-Burnham Medical Research Institute | Compositions and methods for targeted endometriosis treatment |
| TWI636065B (zh) | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| EP3069137A1 (en) | 2013-11-05 | 2016-09-21 | Novartis Ag | Organic compounds |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| US10247729B2 (en) | 2014-05-05 | 2019-04-02 | Microbplex, Inc. | Media elaborated with newly synthesized antibodies (MENSA) and uses thereof |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| MA49157A (fr) | 2014-12-23 | 2021-06-02 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| WO2016141088A1 (en) | 2015-03-02 | 2016-09-09 | Sarcotein Diagnostics, Llc | 13+/17+ bin1 expression as a marker of cardiac disorders |
| RS64397B1 (sr) | 2015-03-27 | 2023-08-31 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003) |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| EP3919507A3 (en) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PT3319985T (pt) | 2015-07-06 | 2021-01-06 | Immatics Biotechnologies Gmbh | Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| CN116375797A (zh) | 2016-03-01 | 2023-07-04 | 伊玛提克斯生物技术有限公司 | 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物 |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| EP3430046A4 (en) | 2016-03-16 | 2019-10-23 | Abeome Corporation | NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF |
| CN109071605A (zh) | 2016-04-06 | 2018-12-21 | 伊玛提克斯生物技术有限公司 | 用于aml和其他癌症免疫治疗的新型肽和肽组合物 |
| MX393609B (es) | 2016-05-18 | 2025-03-24 | Boehringer Ingelheim Int | Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer |
| TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| CA3039532A1 (en) | 2016-10-05 | 2018-04-12 | University Of Central Florida Research Foundation, Inc. | Methods and compositions related to nk cell and anti-pdl1 cancer therapies |
| US20230139592A1 (en) | 2016-12-22 | 2023-05-04 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| WO2018138257A1 (en) | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201701404D0 (en) | 2017-01-27 | 2017-03-15 | Micropharm Ltd | Therapies for treating inflammatory disorders |
| WO2018167486A1 (en) | 2017-03-15 | 2018-09-20 | Oxford Biomedica (Uk) Limited | Method |
| EP3600419B1 (en) | 2017-03-20 | 2023-08-09 | Vaccinex, Inc. | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
| WO2018183488A1 (en) | 2017-03-28 | 2018-10-04 | Ohio State Innovation Foundation | Human pd1 peptide vaccines and uses thereof |
| EP3385699A1 (en) | 2017-04-07 | 2018-10-10 | Universitat Rovira i Virgili | Optofluidic device and method for detecting circulating tumour cells |
| EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| US11427614B2 (en) | 2017-04-10 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| MA49122A (fr) | 2017-04-10 | 2021-03-24 | Immatics Biotechnologies Gmbh | Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse |
| KR20250007011A (ko) | 2017-07-07 | 2025-01-13 | 이매틱스 바이오테크놀로지스 게엠베하 | Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| CA3068203A1 (en) | 2017-07-14 | 2019-01-17 | The Francis Crick Institute Limited | Analysis of hla alleles in tumours and the uses thereof |
| WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY |
| MA49426B1 (fr) | 2017-10-02 | 2022-09-30 | Laboratorios Silanes S A De C V | Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2 |
| WO2019118686A1 (en) | 2017-12-13 | 2019-06-20 | North Carolina State University | Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| EP3802616A4 (en) | 2018-06-04 | 2022-03-30 | University of Maryland, Baltimore | PROCEDURES FOR THE PREVENTION OF AN ACUTE KIDNEY LESION |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| EP3813884B1 (en) | 2018-06-29 | 2024-09-18 | North Carolina State University | In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| US20220267435A1 (en) | 2018-10-03 | 2022-08-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting |
| GB201818477D0 (en) | 2018-11-13 | 2018-12-26 | Emstopa Ltd | Tissue plasminogen activator antibodies and method of use thereof |
| WO2020115223A1 (en) | 2018-12-05 | 2020-06-11 | Katholieke Universiteit Leuven | S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| EP4400840A3 (en) | 2018-12-27 | 2025-02-12 | University Of Utah Research Foundation | Compositions and methods useful in detecting and treating multiple sclerosis and other demyelinating diseases |
| WO2020206233A1 (en) | 2019-04-04 | 2020-10-08 | Vanderbilt University | Therapeutic antibodies for treating lung cancer |
| WO2020225549A1 (en) | 2019-05-06 | 2020-11-12 | The Francis Crick Institute Limited | Method for preventing inflammation |
| US11660330B2 (en) | 2019-06-21 | 2023-05-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| KR20220081977A (ko) | 2019-09-18 | 2022-06-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 스캐폴드를 포함하는 pd-l1 결합분자(pd-l1 binding molecules comprising shiga toxin a subunit scaffolds) |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| TWI878355B (zh) | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| CN115485392A (zh) | 2020-01-24 | 2022-12-16 | 范德比尔特大学 | 用于鉴别配体阻断性抗体及用于确定抗体效价的方法 |
| EP4146327A1 (en) | 2020-05-08 | 2023-03-15 | Novocure GmbH | Compositions and methods of applying alternating electric fields to pluripotent stem cells |
| CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| EP4153590A4 (en) | 2020-05-21 | 2024-06-19 | Ohio State Innovation Foundation | FUNCTIONAL LIPID DERIVATIVES AND THEIR USES |
| TW202229312A (zh) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物 |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
| EP4262858A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| EP4433084A1 (en) | 2021-11-19 | 2024-09-25 | Lykera Biomed, S.A. | Treatment and diagnosis of diseases associated to pathogenic fibrosis |
| CN114132883B (zh) * | 2021-11-29 | 2023-12-22 | 义乌市奥飞创意设计有限公司 | 一种可降低气溶胶污染的血清蛋白抑制剂注射装载设备 |
| WO2024013315A1 (en) | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| WO2024102962A1 (en) | 2022-11-10 | 2024-05-16 | Immuvia Inc | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof |
| WO2025040598A2 (en) | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL186239B (nl) | 1975-06-05 | Hoechst Ag | Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze. | |
| US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
| US4603106A (en) | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| CA1208546A (en) | 1981-09-08 | 1986-07-29 | Anthony Cerami | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US4822776A (en) | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| CA1260828A (en) | 1983-07-04 | 1989-09-26 | Masakazu Iwai | Therapeutic and prophylactic agent for gastrointestinal ulcers |
| DE3342870A1 (de) | 1983-11-26 | 1985-06-05 | Boehringer Mannheim Gmbh, 6800 Mannheim | Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US4849352A (en) * | 1984-10-09 | 1989-07-18 | Sullivan John B | Antibody purification process |
| US4684623A (en) | 1985-05-02 | 1987-08-04 | The Board Of Trustees Of The Cetus Corporation | Use of tumor necrosis factor as a weight regulator |
| DE3650150T2 (de) | 1985-08-16 | 1995-04-27 | The Rockefeller University, New York, N.Y. | Modulator der anabolischen Aktivität und seine Verwendungen. |
| US4870163A (en) * | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| US4918163A (en) | 1985-09-27 | 1990-04-17 | Pfizer Inc. | Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria |
| US4731244A (en) * | 1985-11-13 | 1988-03-15 | Ortho Pharmaceutical Corporation | Monoclonal antibody therapy |
| EP0288520B1 (en) | 1986-10-09 | 1995-05-24 | Neorx Corporation | Use and composition for improved targeting of antibody, antibody fragments, and conjugates thereof |
| US5183657A (en) * | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
| GB8805792D0 (en) * | 1988-03-11 | 1988-04-13 | Celltech Ltd | Medicaments |
| DE3823804A1 (de) * | 1988-07-14 | 1990-01-18 | Basf Ag | Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten |
| JP2638652B2 (ja) | 1988-07-18 | 1997-08-06 | カイロン・コーポレーション | カケクチンと反応するモノクロナール抗体 |
| AU4182289A (en) | 1988-08-19 | 1990-03-23 | Celltech Limited | Pharmaceutical products for anti-neoplastic therapy |
| SG43205A1 (en) | 1988-12-19 | 1997-10-17 | American Cyanamid Co | A method for the treatment of endotoxic shock in a mammal |
| GB8905400D0 (en) * | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
| DE69027121T3 (de) * | 1989-08-07 | 2001-08-30 | Peptech Ltd., Dee Why | Bindeligande für tumornekrosisfaktor |
| GB8918232D0 (en) * | 1989-08-10 | 1989-09-20 | Opal Stephen M | Pharmaceutical product for the treatment of septic shock |
| HUT64481A (en) | 1989-12-04 | 1994-01-28 | Schering Corp | Method for producing pharmaceutical preparative containing human il-6 antagonist |
| US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
| GB9023783D0 (en) | 1990-11-01 | 1990-12-12 | Celltech Ltd | Pharmaceutical product |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| EP1681305A3 (en) | 1991-03-18 | 2008-02-27 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| SK285960B6 (sk) | 1991-07-25 | 2007-12-06 | Biogen Idec Inc. | Rekombinantné protilátky na liečenie ľudí |
| WO1993011793A1 (en) * | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
| ATE155043T1 (de) | 1992-10-08 | 1997-07-15 | Kennedy Inst Of Rheumatology | Behandlung von autoimmun- und entzundungskrankheiten |
| AU5669894A (en) | 1992-11-16 | 1994-06-08 | Corporation Of Mercer University | Compositions using microencapsulated neutralizing antibodies |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
-
1994
- 1994-06-03 CA CA002163032A patent/CA2163032C/en not_active Expired - Fee Related
- 1994-06-03 JP JP7501460A patent/JP2953782B2/ja not_active Expired - Fee Related
- 1994-06-03 US US08/256,053 patent/US5733742A/en not_active Expired - Fee Related
- 1994-06-03 AT AT94917087T patent/ATE157100T1/de not_active IP Right Cessation
- 1994-06-03 DK DK94917088T patent/DK0703925T3/da active
- 1994-06-03 EP EP98203383A patent/EP0916678A3/en not_active Withdrawn
- 1994-06-03 AU AU68525/94A patent/AU6852594A/en not_active Abandoned
- 1994-06-03 ES ES94917087T patent/ES2108460T3/es not_active Expired - Lifetime
- 1994-06-03 NZ NZ266838A patent/NZ266838A/en not_active IP Right Cessation
- 1994-06-03 AT AT94917088T patent/ATE183513T1/de not_active IP Right Cessation
- 1994-06-03 WO PCT/GB1994/001209 patent/WO1994029347A1/en not_active Ceased
- 1994-06-03 DE DE69420137T patent/DE69420137T2/de not_active Expired - Fee Related
- 1994-06-03 FI FI955798A patent/FI955798A7/fi unknown
- 1994-06-03 EP EP94917088A patent/EP0703925B1/en not_active Expired - Lifetime
- 1994-06-03 WO PCT/GB1994/001210 patent/WO1994029348A2/en not_active Ceased
- 1994-06-03 ES ES94917088T patent/ES2138662T3/es not_active Expired - Lifetime
- 1994-06-03 GB GB9524064A patent/GB2294267B/en not_active Expired - Fee Related
- 1994-06-03 US US08/256,155 patent/US6193969B1/en not_active Expired - Lifetime
- 1994-06-03 DE DE69405102T patent/DE69405102T2/de not_active Expired - Lifetime
- 1994-06-03 EP EP94917087A patent/EP0701571B1/en not_active Expired - Lifetime
- 1994-06-03 DK DK94917087.2T patent/DK0701571T3/da active
- 1994-06-03 RU RU96101193A patent/RU2139092C1/ru active
- 1994-06-03 AU AU68524/94A patent/AU678483B2/en not_active Ceased
-
1995
- 1995-11-17 NO NO954643A patent/NO954643D0/no not_active Application Discontinuation
-
1997
- 1997-10-22 GR GR970402765T patent/GR3025133T3/el unknown
-
1999
- 1999-10-07 GR GR990402504T patent/GR3031415T3/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU96101193A (ru) | Фрагменты антител в терапии | |
| CA2261630C (en) | Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease | |
| US5143727A (en) | Method for preventing diarrhea | |
| EA200101064A1 (ru) | Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами | |
| EP0701571A1 (en) | ANTIBODY FRAGMENTS IN THERAPY | |
| IL104880A (en) | Pharmaceutical composition comprising antigen for autoimmune diseases suppression | |
| US20070141058A1 (en) | Method of correcting immunopathological reactions and a medicament | |
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| Aghamohammadi et al. | Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency | |
| RU2004137823A (ru) | Терапевтическое средство против гиперкальциемического криза | |
| ATE144149T1 (de) | Therapeutisches verfahren zur behandlung von iddm | |
| HU9200107D0 (en) | Process for preventing or treating autoimmun uveoretinitis in mammals | |
| IL95457A0 (en) | Preparation containing immunoconjugates for detection and treatment of infections | |
| NZ284914A (en) | use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration | |
| RU2089247C1 (ru) | Способ лечения онкологических больных | |
| RU95112520A (ru) | Применение 4'-йодо-4'-деоксидоксорубицина для лечения амилоидоза, способ лечения амилоидоза | |
| SU1261665A1 (ru) | Способ лечени тимомегалии у детей | |
| RU2197990C2 (ru) | Способ лечения лиц, страдающих от сепсиса | |
| US5081129A (en) | Method of treatment of anemia with seratonin antagonists | |
| Gelfand | Agammaglobulinemia associated with Australia-antigen-positive chronic active hepatitis | |
| WO2004053064A3 (en) | Engineered fab'fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs | |
| SU1105202A1 (ru) | Способ лечени больных звенной болезнью желудка и двенадцатиперстной кишки | |
| Leövey et al. | Myasthenia gravis: ALG treatment of seriously ill patients | |
| Lane et al. | Dermatomyositis following chronic staphylococcal joint sepsis. | |
| RU2008007C1 (ru) | Способ лечения острого вирусного гепатита |